Dr. Levi Garraway

Nationalität
USA

Geburtsjahr
1968

1990
Biochemie, Harvard Medical School, A.B. 

1999
Biochemie und Molekulare Pharmakologie, Harvard Medical School, Ph.D. 

1999
Medizin, Harvard Medical School, M.D.

1999–2001
Massachusetts General Hospital, Internship and Residency in Innere Medizin

2001
Dana-Farber/Partners CancerCare, Fellowship in Medizinischer Onkologie

2003
Department of Medicine, Massachusetts General Hospital, Chief Resident

2004–2005
Laboratory of William Sellers, Dana-Farber Cancer Institute, Research Fellow

2005–2007
Dana-Farber Cancer Institute, Harvard Medical School, Instructor

2007–2011
Dana-Farber Cancer Institute, Harvard Medical School, Assistant Professor Medizin

2010–2016
Foundation Medicine, Mitgründer und Berater

2011–2016
Dana-Farber Cancer Institute, Harvard Medical School, Associate Professor Medizin

2017
Eli Lilly and Company, Senior Vice-President, Globale Onkologie

2017
Tango Therapeutics, Co-Founder

2018
Eli Lilly and Company, Senior Vice-President Oncology R&D and Novel Target Research

Seit 2019
Roche Basel, Executive Vice-President, Leiter der Globalen Produktentwicklung und Chief Medical Officer

–

–

2002–2007
Instructor, Harvard Medical School

2005–2016
Associate Physician Medizin, Brigham and Women’s Hospital

2006–2010
Associate Member, Krebsprogramm, Broad Institute of Massachusetts Institute of Technology (MIT) und Harvard

2006–2016
Mitglied, Biologische und Biomedizinische Wissenschaften Graduierten  Programm, Abteilung für Biologische Chemie & Molekulare Pharmakologie, Harvard Medical School

2007–2011
Assistant Professor Medizin, Harvard Medical School

2010–2014
Senior Associate Member, Broad Institute

2011–2016
Assistant Professor Medizin, Harvard Medical School

2014–2016
Senior Associate Member, Broad Institute

2014–2016
Institute Member, Broad Institute

2016
Investigator, Howard Hughes Medical Institute

Seit 2020
Adjunct Professor, Department of Genetics, Stanford University School of Medicine

2007–2016
Consultant, Novartis Institutes for Biomedical Research

2008–2009
Consultant, Clinical & Translational Research Center, Harvard Medical School

2009–2011
Scientific Task Force, Lymphangioleiomyomatosis (LAM) Treatment Alliance

Seit 2011
Mitglied, Board of Scientific Consultants, Memorial Sloan-Kettering Cancer Center

2011–2016
Mitglied, External Scientific Advisory Board, The Ohio State University Comprehensive Cancer Center

Seit 2013
Mitglied, External Scientific Advisory Board, MD Anderson Cancer Center

2014–2016
Vorsitz, External Scientific Advisory Board, IGNITE Program, National Human Genome Research Institute (NHGRI)

Seit  2015
Mitglied, The V Foundation Scientific Advisory Board

2000–2003
National Medical Association

Seit 2007
American Association for Cancer Research

Seit 2009
American Society for Clinical Investigation

Seit 2010
American Association for the Advancement of Science

2011–2013
American Society for Biochemistry and Molecular Biology

Seit 2012
American Society for Clinical Oncology

Seit 2015
Association of American Physicians

Seit 2020
National Academy of Medicine

2003
Partners in Excellence Award

2007
NIH Director’s New Innovator Award

2009
American Society for Clinical Investigation (President, 2015)

2012
Block Award for Outstanding Cancer Research

2013
Paul Marks Prize for Cancer Research

2014
AACR-MICR Jane Cooke Wright Award

2014
Society for Melanoma Research Outstanding Investigator Award

2015
NCI Outstanding Investigator Award

2015
Association of American Physicians

2019
Academy of Fellows, American Association for Cancer Research

2019
Honorary doctorate, Feinstein Institute

2020
National Academy of Medicine

2022
Margaret J. Foti Award for Leadership and Extraordinary Achievement in Cancer Research

2022
Memorial Sloan-Kettering Medal and honorary doctorate, Gerstner/Sloan-Kettering Graduate School of Biomedical Sciences